Feldan Therapeutics, a Québec City, Québec, Canada-based early clinical-stage pharmaceutical company, received an investment from Zynext Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO François-Thomas Michaud, Feldan is a clinical-stage pharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutics. Its proprietary peptide-based technology, the Feldan Shuttle, enables the delivery of antisense oligonucleotides into cells, generating new therapies.
the company’s pipeline expansion is focused on skin and lung diseases. Its lead product for BCC (FLD-103) is in a Phase 1/2a clinical trial.
FinSMEs
17/04/2025